Search
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalAVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.
Mepartricin
go.drugbank.com/drugs/DB13633InvestigationalCategories: Drugs Used in Benign Prostatic HypertrophySNX-5422
go.drugbank.com/drugs/DB06070InvestigationalAs an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Naftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Tri...
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular deg...
Dopexamine
go.drugbank.com/drugs/DB12313ApprovedWithdrawnDopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.
Lexaptepid pegol
go.drugbank.com/drugs/DB12578InvestigationalLexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
Meticrane
go.drugbank.com/drugs/DB13284ApprovedIt has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].
D-3082-L
go.drugbank.com/drugs/DB17440ExperimentalD-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.
Synonyms: Human Papilloma Virus (HPV) Type 16 E6/e7 Synthetic Long Peptide (SLP) Vaccine Component D-3082-LPalazestrant
go.drugbank.com/drugs/DB18971InvestigationalPalazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).